Pfizer Misses Q4 Target, offers Soft Guidance
Pfizer (PFE) stock stumbled as the company reported lower than expected numbers for its fourth quarter. It also provided lackluster guidance for the upcoming FY 2020. The company’s revenue fell as it lost exclusivity on its key drugs. Pfizer transferred its consumer health business to a joint venture and the impact of this move was visible on the quarterly numbers.
Pfizer reported net loss of $0.06 per share for the fourth quarter, slightly down from net loss of $0.07 per share for the corresponding quarter of